Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility

Obesity Clinical Trial

— SWIFT-CORE-101  

Official title:

Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility (SWIFT-CORE-101)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06412536
• Other study ID #: CORE042024
• Status: Recruiting
• Start date: May 30, 2024
• Est. completion date: April 17, 2029

Study information

• Verified date: May 2024
• Source: Brooklyn Clinical Research
• Contact: Ammara Mushtaq, MD
• Phone: 929-203-5879
• Email: amushtaq[@]brooklynclinicalresearch.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, comorbidities, and current symptoms. Site staff may collect vital signs, urine drug screens, blood draws, and urine pregnancy tests. A doctor will review medical history with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians and pharmacies to determine eligibility for clinical trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: April 17, 2029
• Est. primary completion date: April 10, 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.

2. Participant is at least 18 years old.

Exclusion Criteria:

1. Participant is pregnant, breast-feeding, or planning to become pregnant.

2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.

3. Moderate or severe substance use disorder within 90 days prior to screen

4. Any condition that in the investigator's opinion makes a participant unsuitable for the study.

5. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes Mellitus, Type 2
• Diabetes Type 2
• Metabolic Syndrome
• Obesity
• PreDiabetes

Intervention

Other:
• Blood work
Blood work on some participants to review eligibility for future clinical trials

Locations

Country	Name	City	State
United States	Brooklyn Clinical Research	Brooklyn	New York

Sponsors (1)

Lead Sponsor	Collaborator
Brooklyn Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants who are interested in industry-sponsored clinical research	Number of participants who are interested in industry-sponsored clinical research in each of the following therapeutic areas: cardiovascular, obesity, and endocrine.	5 years
Secondary	Characteristics associated with patient populations interested in clinical trials	Characteristics associated with patient populations interested in clinical trials stratified by demographics and therapeutic areas	5 years